Lab Members

Aude Chapuis, MD

Aude Chapuis, MD

Title: Principal Investigator
Phone: 206.667.4369

Clinical Research Division, Program in Immunology
View faculty profile

Shihong Zhang, PhD

Shihong Zhang, PhD

Title: Staff Scientist
Area of Responsibility: Shihong's work focuses on improving the efficacy of TCR T cell therapy by adding a costimulatory receptor to the T cells. She now has multiple costimulatory receptor candidates that can increase the binding of TCR T cells to tumor cells and/or give the T cells additional stimulation signals to help with the fitness and functionality of the T cells. She will find the winning receptor by next generation sequencing after in vitro and in vivo stimulation of mixed T cells, and eventually take it to the clinics.
Denise Buenrostro, PhD

Denise Buenrostro, PhD

Title: Post-Doctoral Research Fellow
Area of Responsibility: Denise is working on common DNA viruses that cause serious complications and even death for post-transplant patients. The goal is to engineer and transfer virus-specific T cells that will enhance their virus-specific T cell immunity. If we can control viral reactivation and infection, we can save more lives.
Sinéad Kinsella, PhD

Sinéad Kinsella, PhD

Title: Staff Scientist
Area of Responsibility: Sinéad is focused on TCR discovery and metabolic regulation of antigen presentation across multiple tumor types. Previously, Sinéad’s research has centered on the molecular mechanisms of immune regeneration and enhancing immune function in response to cytoreductive therapies.
Yuta Asano

Yuta Asano

Title: Post Doctoral Research Fellow
Area of Responsibility: Yuta is working on development of T-cell immunotherapy for Merkel cell carcinoma. Outside the lab, he enjoys bouldering and chilling with his cat.
Tianzi Zhang

Tianzi Zhang

Title: Post Doctoral Research Fellow
Area of Responsibility: Tianzi is working on developing a high-throughput screening system that enables rapid patient-specific CD8+ TCR-antigen pair discovery. By using single-cell transcriptomic sequencing and TCR sequencing, the TCRs with high antigen specificity and anti-tumor reactivity will be engineered in lab and translated into the clinic.
Elise Wilcox, PhD

Elise Wilcox, PhD

Title: Post Doctoral Research Fellow
Area of Responsibility: Elise has a B.S. in Biomedical Engineering from Yale University and a Ph.D. in Medical Engineering and Medical Physics from a joint program between MIT and Harvard Medical School. Her graduate work focused on how microenvironment, specifically the surfaces cells adhere to, affect the phenotype of and immune response to allogeneic endothelial cells. Outside of the lab, she loves running, baking, and flying small planes.
Miranda Lahman

Miranda Lahman

Title: Graduate Student
Area of Responsibility: Miranda is a graduate student in the UW School of Medicine’s M3D program. Her research advances next generation TCR therapies by helping us understand what happens when cancer resists these treatments. Her PhD thesis has two main foci. The first is understanding how cancer can modify peptide processing (primarily done by the proteasome) to confer resistance to our T cell receptor (TCR) based therapies. The second a collaboration with the Strong lab to use their innovative peptide discovery platform, Atremis. She is particularly interested in using this technology to understand the contribution of individual proteasome isoforms to the immunopeptidome to reveal new TCR therapy targets.
Lauren Martin

Lauren Martin

Title: Research Technician
Bo Lee

Bo Lee

Title: Research Technician
Area of Responsibility: Bo is working to develop target reporters to identify the targets of anti-tumor T cells residing in the tumors of cancer patients. She is also assisting in developing processes to support clinical products and IND generation to enable clinical trial initiation.
Alex Tang

Alex Tang

Title: Research Technician
David Ahmann

David Ahmann

Title: Research Technician
Area of Responsibility: David maintains the lab spaces, ensuring they are clean and operational. He also partners with Miranda to utilize the ARTEMIS pipeline (Strong Lab) to understand antigen processing/presentation and to discover targetable leukemia peptides.